Steven K. Burke - Feb 28, 2022 Form 4 Insider Report for Akebia Therapeutics, Inc. (AKBA)

Role: SVP, Chief Medical Officer
Signature: /s/ Carolyn Rucci, attorney-in-fact for Steven K. Burke
Stock symbol: AKBA
Transactions as of: Feb 28, 2022
Transactions value $: -$32,564
Form type: 4
Date filed: 3/2/2022, 08:12 PM
Previous filing: Sep 2, 2021
Next filing: May 16, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AKBA	Common Stock	Sale	-$15.9K	-7.4K	-4.32%	$2.15	164K	Feb 28, 2022	Direct	F1
transaction	AKBA	Common Stock	Award	$0	+60K	+36.63%	$0.00	224K	Feb 28, 2022	Direct	F2
transaction	AKBA	Common Stock	Sale	-$14.2K	-6.56K	-2.93%	$2.17	217K	Mar 1, 2022	Direct	F3
transaction	AKBA	Common Stock	Sale	-$2.39K	-1.1K	-0.5%	$2.17	218K	Mar 1, 2022	Direct	F4, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AKBA	Employee Stock Option (Right to buy)	Award	$0	+225K		$0.00	225K	Feb 28, 2022	Common Stock	225K	$2.16	Direct	F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 26, 2021.
F2	The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. One-third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date.
F3	This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 28, 2020.
F4	This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the performance-based restricted stock units that were previously reported for the Reporting Person on a Form 4 filed on March 18, 2021.
F5	Includes 1,500 shares of the Issuers common stock purchased on December 31, 2021, under the Issuers 2014 Amended and Restated Employee Stock Purchase Plan.
F6	The options were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date.